search

Active clinical trials for "Thyroid Cancer, Papillary"

Results 51-60 of 123

Percutaneous Ethanol Injection for Primary Papillary Thyroid Microcarcinoma

Papillary Thyroid Cancer

We assess the effectiveness of percutaneous ethanol ablation for the treatment of thyroid cancer.

Terminated14 enrollment criteria

A Home-Based Approach Study to Evaluate the Efficacy and Safety of Alectinib in Locally-Advanced...

NeoplasmsColorectal Neoplasms30 more

This study will evaluate the efficacy and safety of alectinib in participants with Anaplastic Lymphoma Kinase (ALK)-positive locally advanced or metastatic solid tumors other than lung cancer.

Terminated29 enrollment criteria

Lenvatinib and Iodine Therapy in Treating Patients With Radioactive Iodine-Sensitive Differentiated...

Differentiated Thyroid Gland CarcinomaThyroid Gland Follicular Carcinoma1 more

This phase II trial studies how well lenvatinib works when given together with standard of care iodine I-131 in treating patients with radioactive iodine-sensitive differentiated thyroid cancer. Lenvatinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

Terminated28 enrollment criteria

Adaptive Tyrosine Kinase Inhibitor (TKI) Therapy In Patients With Thyroid Cancer

Thyroid CancerThyroid Cancer5 more

Participants will have been diagnosed with advanced progressive thyroid cancer and are about to start treatment with a tyrosine kinase inhibitor (TKI). The purpose of this study is to evaluate the efficacy and tolerability of tyrosine kinase inhibitor therapy (Lenvatinib or Sorafenib for differentiated thyroid cancer [which includes papillary thyroid cancer, follicular thyroid cancer, and poorly differentiated thyroid cancer]; and Cabozantinib or Vandetanib for medullary thyroid cancer) through adaptive (intermittent) versus conventional (continuous) regimen.

Terminated40 enrollment criteria

Potential Role for Carbon Nanoparticles to Guide Central Neck Dissection in Patients With Papillary...

Thyroid Cancer

Papillary thyroid cancer (PTC) is the most common subtype of thyroid cancer. The most common site of PTC nodal metastases is the central neck, which has a reported rate of lymph node metastases as high as 50%~70%. Central neck dissection has important value to ensure accurate clinical staging and surgical planning. As a novel lymphatic tracer, carbon nanoparticles (CN) have been applied successfully in the detection of sentinel lymph nodes in breast and gastric cancers, while not been used as a lymphatic tracer for PTC. The goal of this study was to evaluate whether the use of CN facilitates the detection of lymph nodes, increases the number of metastatic lymph nodes removed, accurately reflects the metastatic condition of the central neck, and has the potential to protect the parathyroid glands.

Completed10 enrollment criteria

Effects of Radioactive Iodine on the Immune System in Thyroid Cancer

Thyroid CarcinomaNonmedullary

Blood will be drawn 1 month before and 2 month after regular radioactive iodine treatment. Monocytes will be isolated. The three main outcomes are whole blood counts, cytokine production upon in vitro stimulation of monocytes and in vitro ROS production by monocytes. These results are compared between patients treated in adjuvant setting and patients treated for persistent structural disease, and between pre- and post-treatment status.

Not yet recruiting9 enrollment criteria

A Study of Vemurafenib (RO5185426) in Participants With Metastatic or Unresectable Papillary Thyroid...

Neoplasms

This open-label, multi-center study will evaluate the safety and efficacy of Vemurafenib (RO5185426) in participants with metastatic or unresectable papillary thyroid cancer (PTC) positive for the BRAF V600 mutation and resistant to radioactive iodine therapy. Participants will receive vemurafenib 960 milligrams (mg) orally twice daily until progressive disease or unacceptable toxicity occurs.

Completed16 enrollment criteria

Study of XL281 in Adults With Solid Tumors

CancerNon-small-cell Lung Cancer3 more

The purpose of this study is to determine the safest dose of the multiple Raf kinase inhibitor (including c-Raf, B-Raf, and the activated mutant B-RafV600E) XL281, how often it should be taken, and how well subjects with cancer tolerate XL281. This study will also determine how the body reacts to XL281 when it is taken with and without food, and with and without Pepcid (famotidine), a drug that inhibits stomach acid production.

Completed24 enrollment criteria

Photodynamic Therapy Using HPPH in Treating Patients Undergoing Surgery for Primary or Recurrent...

Recurrent Adenoid Cystic Carcinoma of the Oral CavityRecurrent Basal Cell Carcinoma of the Lip53 more

This phase I trial studies the side effects and best dose of photodynamic therapy using HPPH in treating patients who are undergoing surgery for primary or recurrent head and neck cancer. Photodynamic therapy (PDT) uses a drug, such as HPPH, that becomes active when it is exposed to a certain kind of light. When the drug is active, tumor cells are killed. Giving photodynamic therapy after surgery may kill any tumor cells that remain after surgery.

Completed17 enrollment criteria

Sunitinib Malate in Treating Patients With Iodine-Refractory Recurrent or Metastatic Thyroid Cancer...

Recurrent Thyroid CancerStage IVA Follicular Thyroid Cancer6 more

This phase II trial studies how well giving sunitinib malate works in treating patients with iodine-refractory recurrent or metastatic thyroid cancer. Sunitinib malate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth or by blocking blood flow to the tumor

Completed29 enrollment criteria
1...567...13

Need Help? Contact our team!


We'll reach out to this number within 24 hrs